Suparna C. Clasen
YOU?
Author Swipe
View article: SGLT2 Inhibitor for Cardiac Protection in a Patient With Osimertinib-Responsive Advanced EGFR-Positive Lung Cancer
SGLT2 Inhibitor for Cardiac Protection in a Patient With Osimertinib-Responsive Advanced EGFR-Positive Lung Cancer Open
View article: Cardiovascular disease in thymic cancer patients
Cardiovascular disease in thymic cancer patients Open
Introduction Cancer patients may have increased risk for adverse cardiac events, but our understanding of cardiovascular risk in thymic cancer patients is not clear. We sought to characterize baseline cardiometabolic risk factors before th…
View article: How to Manage Cisplatin-Based Chemotherapy–Related Cardiovascular Disease in Patients With Testicular Cancer
How to Manage Cisplatin-Based Chemotherapy–Related Cardiovascular Disease in Patients With Testicular Cancer Open
[Figure: see text]
View article: Cisplatin, environmental metals, and cardiovascular disease: an urgent need to understand underlying mechanisms
Cisplatin, environmental metals, and cardiovascular disease: an urgent need to understand underlying mechanisms Open
View article: Early Cardiac Effects of Contemporary Radiation Therapy in Patients With Breast Cancer
Early Cardiac Effects of Contemporary Radiation Therapy in Patients With Breast Cancer Open
View article: Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity
Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity Open
View article: Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia
Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia Open
Results from several recent studies in chronic lymphocytic leukemia (CLL) have demonstrated an association between ibrutinib exposure and the development of atrial fibrillation, estimated incidence of 11% with long-term follow up. This is …
View article: Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm
Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm Open
We report a single-institution experience of successful rechallenge with fluoropyrimidines with careful cardiac monitoring and the combined use of calcium channel blockers and long-acting nitrates. With further study, this algorithm can be…